CONGRESS ABSTRACT

Background: Takotsubo syndrome may follow an abruptadrenergic discharge; pheochromocytoma-related forms are uncommon but tend to be severe, with ischaemia/vasospasm, pulmonary oedema, arrhythmias and shock. Case presentation: A 57-year-old woman with long-standing paroxysmal hypertension and a 5-cm right adrenal mass wasadmitted for morpho-functional assessment of suspectedpheochromocytoma. During the diagnostic pathway,…

Background. The association between hyperthyroidism and acute myocarditis has been already reported in literature; however, this case presents an unusual scenario without classical hyperthyroidism symptoms or infective myocarditis features, in which the coexistence with thyrotoxicosis suggests a possible but unproven relationship. Case presentation. A 26-year-old male presented with acute…

BACKGROUND Resistant arterial hypertension carries a high cardiovascular risk and remains challenging to control. Renal sympathetic denervation (RDN) is an interventional option for carefully selected patients. CLINICAL CASE A 58-year-old man presented with long-standing resistant arterial hypertension. Past medical history included recent NSTEMI treated with drug-coated balloon angioplasty, peripheral…

Background: Narrative Medicine captures the lived experience of acute myocardial infarction (AMI) and may reveal sex- and gender-related patterns that shape symptom interpretation, emergency activation, adherence and rehabilitation. NARGEN maps post-AMI narratives to generate actionable targets for personalized secondary prevention. Methods: NARGEN is an observational, single-centre narrative-medicine study at…

Background: Takotsubo cardiomyopathy ( TTS ) is an acute,typically reversible form of stress-induced left ventricular dysfunction characterized by transient non-coronary wall motion abnormalities.It’s often triggered by severe physical or emotional stress,viral infections and neurological disorders.The occurrence of TTS in the specific context of West Nile Virus encephalitis is exceedingly…

Introduction: In HELIOS-B(NCT04153149), vutrisiran significantly reduced the risk of the primary endpoint composite of all-cause mortality(ACM) and recurrent cardiovascular(CV) events, and met all secondary endpoints(including ACM at 42months), vs placebo in patients with transthyretin amyloidosis with cardiomyopathy(ATTR-CM) in both the overall and monotherapy (patients not receiving tafamidis at baseline)…